Abstract:Heparins have been invaluable therapeutic anticoagulant polysaccharides for over a century, whether used as unfractionated heparin or as low molecular weight heparin (LMWH) derivatives. However, heparin production by extraction from animal tissues presents multiple challenges, including the risk of adulteration, contamination, prion and viral impurities, limited supply, insecure supply chain, and significant batch-to-batch variability. The use of animal-derived heparin also raises ethical and religious concerns, as well as carries the risk of transmitting zoonotic diseases. Chemoenzymatic synthesis of animal-free heparin products would offer several advantages, including reliable and scalable production processes, improved purity and consistency, and the ability to produce heparin polysaccharides with molecular weight, structural, and functional properties equivalent to those of the United States Pharmacopeia (USP) heparin, currently only sourced from porcine intestinal mucosa. We report a scalable process for the production of bioengineered heparin that is biologically and compositionally similar to USP heparin. This process relies on enzymes from the heparin biosynthetic pathway, immobilized on an inert support and requires a tailored N-sulfoheparosan with N-sulfo levels similar to those of porcine heparins. We also report the conversion of our bioengineered heparin into a LMWH that is biologically and compositionally similar to USP enoxaparin. Ultimately, we demonstrate major advances to a process to provide a potential clinical and sustainable alternative to porcine-derived heparin products.

Immobilized high-performance heparin lyase III for efficient preparation of low molecular weight heparin

High-Level Expression and Purification of Recombinant Heparinase Ⅰ in Escherichia Coli

Structure-based engineering of heparinase I with improved specific activity for degrading heparin

Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase

Combination of Site-Directed Mutagenesis and Calcium Ion Addition for Enhanced Production of Thermostable MBP-fused Heparinase I in Recombinant Escherichia Coli

Expression, purification, and characterization of recombinant lumbrokinase PI239 in Escherichia coli.

Production of Heparin Oligosaccharides by Fusion Protein of MBP–heparinase I and the Enzyme Thermostability

Controllable production of low molecular weight heparins by combinations of heparinase I/II/III.

Characteristics of low molecular weight heparin production by an ultrafiltration membrane bioreactor using maltose binding protein fused heparinase I

Clonging and Expression of Heparinase III Gene from Flavobacterium heparinum and Characterization of the Recombinant Fusion Enzyme

Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin

Construction of recombinant for over-production of soluble heparinase I by fusion to maltose-binding protein

Construction of MBP fusion heparinaseⅢ efficient expression system inE.coli

Rational Design of a Tripartite Fusion Protein of Heparinase I Enables One-Step Affinity Purification and Real-Time Activity Detection.

Expression, Purification and Characterization of the Recombinant Hirudin Variant Iii in the Bacillus Subtilis

Characterization of Maltose-Binding Protein-Fused Heparinases with Enhanced Thermostability by Application of Rigid and Flexible Linkers

Construction Of Engineered E-Coli System For The Overproduction Of Soluble Heparinase I

Preparation of Low Molecular Weight Heparin Using an Ultrasound-Assisted Fenton-system

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

Enzymatic access to the rare ΔUA (1→4) Glc 3, 6, N-sulfated heparin disaccharide, implications for heparin quality control

Identification and characterization of a novel heparinase PCHepII from marine bacterium Puteibacter caeruleilacunae